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• Medication treatment focuses to 
improve cardiac pump function, 
augment fluid removal, and enhance 
tissue perfusion.  These goals are 
achieved through the use of ACE 
inhibitors, diuretics, and beta blocker 
medications.  
• ACE inhibitors impede the neurohormal 
response of the RAAS system thus 
preventing systemic vasoconstriction 
and water retention. Angiotensin 
receptor blockers (ARBs) also inhibit the 
RAAS system and can be utilized in 
patients who cannot tolerate ACE 
inhibitors.  
• Diuretics are used to decrease 
intravascular volume.  The reduction in 
venous return reduces preload and 
allows the overfilled LV to contract more 
efficiently and improve CO. The increase 
in left ventricular function, decreases 
pulmonary vascular pressures, and 
improves gas exchange. Hydralazine and 
nitroglycerin are additional medications 
that cause systemic vasodilation and a 
reduction in afterload and preload, thus 
eliminating some ventricular strain.  
• Beta-adrenergic blockers directly block 
the negative effects of the SNS on the 
failing heart such as increased HR and 
systemic vasoconstriction. A reduction 
in HR and systemic pressure allows 
increased cardiac perfusion and lower 
pressures to overcome during 
contraction.    
• This medication list is not all-inclusive as 
medication therapies should be tailored 
to each patient. Additionally, new 
medication and surgical therapies are 
being discovered every day.  
• Heart Failure (HF) is an abnormal clinical 
condition involving impaired cardiac 
pumping which results in characteristic 
pathophysiologic changes related to 
vasoconstriction and fluid retention 
(Lewis, Dirksen, Heitkemper, & Butcher, 
2011). 
• In most nations, HF has become a major 
health problem with increasing 
incidence.  Currently, about 5.1 million 
people in the United States are living 
with heart failure. This equates to an 
estimated $32 billion dollars each year 
in national healthcare costs (Alan et al., 
2013).  
• I have chosen HF as my topic of choice, 
mainly due to its prevalence in the 
patient population that I serve.  I 
currently practice on an intermediate 
unit where most patients suffer from 
multiple comorbidities including some 
form of heart failure.  What I find most 
fascinating about HF is the multiple 
ways the human body attempts to 
compensate for impaired cardiac 
pumping and the clinical symptoms 
associated with its disease process.  HF 
can influence a multitude of body 
systems including the sympathetic 
nervous system, kidney, immune and 
pulmonary systems.   
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Implications for  
nursing care (cont.) 
• Current treatment for HF involves 
lifestyle changes, patient education, 
disease-modifying and symptom-
controlling medications. 
Unfortunately, none of these 
treatment methods provide a cure for 
HF, but only make symptoms more 
manageable and slow disease 
progression. Because of this, it is of 
paramount importance for both 
patient and provider to understand 
and adhere to education and 
treatment plans.  Only by working 
together can therapeutic goals be 
achieved and quality of life sustained.  
Conclusions 
• The main goals in treatment of HF is to 
treat the underlying cause, maximize 
CO, improve ventricular function, 
provide treatment to alleviate 
symptoms, improve quality of life, and 
improve mortality and morbidity.   
• However, these goals can only be 
achieved if both the patient and 
caregiver and both understanding of 
the patient’s plan of care. Patient’s 
and caregivers require education 
about heart failure to develop the 
staff-patient relationship and improve 
treatment concordance (Nicholson, 
2014).  Education empowers patients, 
increases successful self-management, 
and decreases rates of hospitalization.  
Lifestyle modifications such as diet, 
exercise, and smoking cessation 
should be discussed.   
• Patients should also be taught that 
good control of comorbid conditions 
such as diabetes, high cholesterol, and 
kidney disease improves cardiac 
outcomes (Nicholson, 2014).  
Education of early warning signs such 
as weight gain and respiratory distress 
should also be addressed. 
• Medications are the mainstay of heart 
failure treatment.  Medications can 
relieve symptoms, reduce 
hospitalizations, shorten length of stay 
and improve quality of life and 
prognosis (Nicholson, 2014).  Again, 
treatments such as medications only 
work if the clinician and patient both 
understand the treatment plan and 
then carry it out together. 
 
Implications for  
nursing care 
Neurohormonal Responses: The Renin-Angiotensin-Aldosterone System (RAAS) 
• When the kidney senses a decrease in perfusion, the renin–angiotensin-aldosterone 
system (RAAS) is called into action. Angiotensin II is the primary effector hormone 
secreted in response to physiological stimuli and is formed from its precursor, 
angiotensinogen, by two enzymatic cleavages (Shearer & Struthers, 2013). 
Angiotensinogen, released by the liver, is converted to angiotensin I by the action of 
renin. Angiotensin I is then cleaved by angiotensin converting enzyme (ACE) from the 
lungs to angiotensin II. Circulating angiotensin II promotes aldosterone secretion from 
the adrenal cortex which increases water and sodium reabsorption.  This leads to a 
boost in intravascular fluid volume, and enhanced cardiac preload. It also causes 
systemic vasoconstriction, increasing vascular resistance and cardiac afterload (Shearer 
& Struthers, 2013). 
• Activation of the SNS and the neurohormonal response lead to elevated levels of 
norepinephrine, angiotensin II, aldosterone, endothelin, and proinflammatory 
cytokines. Together these factors result in an increase in cardiac workload, myocardial 
dysfunction, and eventual ventricular remodeling (Lewis et al., 2011). 
Cardiac Remodeling 
• Another compensatory mechanism of the heart (in efforts to maintain adequate CO) is 
ventricular remodeling. Left ventricle (LV) remodeling involves changes in cavity size, 
wall thickness, mass, and shape; all of which reflect adaptations to myocardial injury 
and alterations in LV load (Ky et al., 2012). 
• Dilation is an enlargement of the chambers of the heart and occurs when pressure in 
the heart chambers is elevated overtime. The muscle fibers of the heart stretch to 
accommodate blood volumes in the heart at the end of diastole. At first this added 
stretch leads to increase in contraction force (Frank-Starling Law), but eventually this 
mechanism becomes inadequate because the elastic elements of the muscle fibers are 
overstretched and can no longer contract effectively, thereby decreasing CO (Lewis et 
al., 2011).    
• During chronic HF, the cardiac muscle adapts to volume overload and strain by 
increasing cardiac muscle mass and cardiac wall thickness. This is called hypertrophy.  
Hypertrophy further increases the contractile power of the muscle fibers causing a 
short-term increase in tissue perfusion and CO. However, the hypertrophic heart 
muscle has poor contractility, and requires more oxygen to perform work (Piepoli, & 
Crisafulli, 2014). 
Types of Heart Failure: Left-sided Failure vs. Right-sided Failure  
• HF usually manifests as biventricular failure, however one side may fail while the other 
side continues to function normally for a period of time.  
• Left-sided heart failure is most common and results from left ventricular dysfunction 
which prevents normal blood flow through the aorta and to the body. This causes blood 
to back up into the left atrium and into the pulmonary veins.  The increased pulmonary 
pressure causes fluid extravasation from capillary beds into the interstitium and then 
the alveoli, which presents clinically as pulmonary congestion and edema (Lewis et al., 
2011).  
 
• The primary cause of right-sided 
heart failure is left-sided heart 
failure. As previously mentioned, left-
sided heart failure results in 
pulmonary congestion and pulmonary 
hypertension. Eventually this increase 
in pulmonary pressure causes right-
sided hypertrophy and failure. Right- 
sided failure causes a backup of blood 
into the right atrium and venous 
circulation. The major syndrome of 
RV failure is volume overload and 
fluid retention in the systemic 
circulation, including peripheral 
edema, jugular venous distention, 
and ascites (Guglin & Verma, 2012).  
Signs & Symptoms 
• Clinical presentation of HF will 
depend on the patient’s severity of 
HF and particular pattern of disease. 
• Common manifestations of HF include 
fatigue, dyspnea, exercise 
intolerance, and fluid retention, 
which may lead to pulmonary and 
peripheral edema symptoms such as 
adventitious lung sounds and weight 
gain (Nicholson, 2014).  
• Signs and symptoms of advanced HF 
consist of progressive exertional 
dyspnea, paroxysmal nocturnal 
dyspnea, orthopnea, fatigability, loss 
of appetite, abdominal bloating, and 
nausea or vomiting.   
• HF is caused by any interference with the normal mechanisms of cardiac output 
(CO). CO is dependent on preload, afterload, and myocardial contractility. 
Accordingly, some origins of HF include CAD, cardiomyopathy, valvular disorders, MI, 
dysrhythmias, HTN, and pulmonary disorders (Piepoli & Crisafulli, 2014). 
• Collectively these causes increase the workload of the ventricles, resulting in a 
decompensated condition that leads to decreased myocardial function and an 
impaired ability of the heart to maintain adequate CO.  
• HF is classified as systolic or diastolic. 
• Systolic HF is the most common cause of heart failure and results from the inability 
of the ventricles to contract and pump blood. Systolic failure is a result of impaired 
contractile function which can be caused by increased afterload due to HTN, MI, 
cardiomyopathies, and valvular disorders. The left ventricle (LV) loses the ability to 
generate enough pressure to eject blood forward through the aorta and over time 
the LV becomes dilated, thin-walled, and hypertrophied (Lewis et al., 2011). The 
hallmark of systolic dysfunction is a decrease in the left ventricular ejection fraction.   
• Diastolic Failure is an impaired ability of the ventricles to relax and fill with blood 
during diastole. Decreased filling of the ventricles leads to decreased stroke volume 
and CO. Diastolic failure is characterized by high filling pressures due to stiff or 
noncompliant ventricles. This results in venous backflow in both the pulmonary and 
systemic vascular systems (Komamura, 2013). The diagnosis of diastolic failure is 
made on the basis of the presence of pulmonary congestion, pulmonary 
hypertension, ventricular hypertrophy, and a normal EF (Lewis et al., 2011). 
Underlying Pathophysiology 
Significance of Pathophysiology 
• As the heart begins to fail the body’s metabolic demands, several compensatory 
mechanisms are activated to maintain adequate tissue perfusion and cardiac output. 
The main compensatory mechanisms include the sympathetic nervous system (SNS) 
activation, neurohormonal responses, and cardiac remodeling.  
Sympathetic Nervous System (SNS) Activation 
• Baroreceptors respond to a diminished CO and low BP by stimulating the SNS.  
Activation of SNS promotes the maintenance of cardiovascular homeostasis by 
inducing positive chronotropic and inotropic effects in the heart (increasing HR and 
myocardial contractility), as well as increased peripheral arterial vasoconstriction  
(Souda-Pinto, Ferreira-Pinto, Santos, Leite-Moreira, 2014). 
• Initially these compensatory changes improves CO, however over time these factors 
act in detrimental fashion by increasing the heart’s need for oxygen and the 
workload of the already failing heart (Lewis et al., 2011). Arterial vasoconstriction 
increases CO by causing an increase in preload; however this leads to a higher 
afterload pressure and increase of venous return thus creating additional ventricular 
strain on the already volume overloaded heart.  
• Overactivation of the SNS is an important pathophysiological factor in HF. Although it 
may first be an adaptive response, chronic adrenergic overactivation is considered 
detrimental in the long run because it promotes cardiac remodeling and subsequent 
dysfunction (Andersen, Andersen, de Man, & Nielsen-Kudsk, 2015).  
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